|Day Low/High||1.08 / 1.15|
|52 Wk Low/High||0.91 / 7.60|
The most recent short interest data has been released for the 06/15/2016 settlement date, which shows a 845,388 share decrease in total short interest for Fibrocell Science, Inc. , to 2,622,567, a decrease of 24.38% since 05/31/2016.
Here's a technical look at how to trade several under-$10 stocks that are poised for breakouts.
Fibrocell to focus on gene therapy portfolio of drug candidates
Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT
FCX-013 Gene-Therapy Product Candidate Offers Potential to Address Painful Fibrotic Disease
These under-$10 stock look poised to break out and trade higher from current levels.
Company to Host Conference Call and Webcast, Today at 8:30 a.m. EST
Companies to Develop Best-in-Class Treatment for Arthritis and Related Conditions Through Targeted, Long-term Therapeutic Delivery While Sparing Systemic Effects
The most recent short interest data was recently released by the NASDAQ for the 09/30/2015 settlement date, and Fibrocell Science, Inc. is one of the most shorted stocks of the Russell 3000, based on 8.20 "days to cover" versus the median component at 5.50.
Highlights in vivo Pre-Clinical Data for Potential First-in-Class Treatment for RDEB
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
These stocks look ready to break out and trade higher from current levels.
Company to Host Conference Call and Webcast, Today at 8:30 a.m. EDT